🔗 Share this article

The recently developed medications for gonorrhoea in decades are being described as a "significant breakthrough" in the battle against drug-resistant strains of the infection, according to researchers.

An International Health Concern

Cases of gonorrhoea are on the rise worldwide, with data suggesting more than 82 million new cases per year. Notably increased rates are observed in the African continent and nations within the WHO's designated area, which encompasses China and Mongolia to New Zealand. In England, cases have hit a historical peak, while figures across Europe in 2023 were three times higher compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune development in the context of increasing worldwide cases, escalating drug resistance and the highly restricted treatment choices at this time.”

Health officials are particularly alarmed about the rise in antibiotic-resistant strains. The WHO has designated it as a "priority pathogen". Ongoing monitoring revealed that resistance to key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Therapies Gain Approval

Zoliflodacin, marketed under the name Nuzolvence, was authorized by the US Food and Drug Administration in recent days for use against gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Researchers anticipate that focused deployment of this new drug will help hinder the spread of drug resistance.

Gepotidacin, created by the drugmaker GSK, gained clearance in the same week. This drug, which is additionally indicated for UTIs, was proven in research to be effective against superbug versions of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin stemmed from a new, not-for-profit approach for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm Innoviva to see it through.

“This milestone represents a huge turning point in the management of superbug gonorrhoea, which previously has been staying ahead of medical innovation.”

Clinical Trial Outcomes and Worldwide Availability

According to findings detailed in a prominent scientific publication, zoliflodacin cured more than 90% of cases of the STI. This puts it on an equal footing with the typical regimen, which combines a dual-drug approach. The trial included nearly 1,000 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, GARDP has the ability to register and commercialise the drug in numerous low-income and middle-income countries.

Clinicians directly involved have shared positive views. Access to a single-dose, oral treatment such as this is described as a "game-changer" for gonorrhoea control. This is considered vital to alleviate the strain of the infection for patients and to prevent the spread of highly drug-resistant gonorrhoea worldwide.